MD Integrations alternatives by clinical and operating fit

How should you build this shortlist?

A clinical integration can work well while leaving the brand with substantial commerce, support and technical responsibilities. Decide whether you are replacing the clinical service, expanding its program scope or looking for a more coordinated operating platform. Those are different buying problems and can produce different shortlists.

Write a program brief that names the intended care pathway, patient experience, existing systems and operational owners. Have the relevant clinical team confirm what it can support; do not treat sales categories as prescribing permissions. The white-label guide helps distinguish the infrastructure layers. The alternatives below are evaluated for fit, with strengths and tradeoffs tied to their public models rather than invented performance ratings.

Which alternative fits which buying question?

The following are evaluation routes, not claims that one vendor is universally best. Public-source review date: October 22, 2026. Confirm the current written scope before contracting.

When is TEHR the stronger fit for your operating brief?

TEHR is worth evaluating when the need extends beyond clinical encounters into brand software, payments, recurring subscriptions and administrative coordination. It provides access to an independent licensed clinical network while preserving clinical judgment with the providers. Its commercial structure is a flat subscription and flat transaction fee with 0% revenue share; request a scoped quote.

The strength to assess is the joined-up operation around care. The tradeoff is that your proposal still needs to identify exactly which services are included. TEHR’s operators built DudeMeds, Peptiders, TellyMeds and FansMeds and migrated thousands of their own patients. Ask how that experience translates into your specific workflow and transition, then test the platform with a repeat patient and a support exception.

When should Beluga be evaluated for clinical integration?

Beluga’s platform page presents several integration routes. Consider it if your organization wants to retain its existing commercial experience while evaluating a different arrangement for the clinical layer.

The strength is a choice of connection points; the tradeoff is that the resulting stack may involve components operated by your team or a platform partner. Ask which route is fastest for your actual environment and which work remains outside the quote. Evaluate patient messaging, clinical-record access and fulfillment status in that exact route. Do not assume a general demo shows the configuration you will receive. The Beluga comparison helps distinguish the clinical backend from the patient-facing systems around it.

When does Lithos fit a team that owns its product?

Lithos positions a medical practice behind the customer’s application. It is relevant when you have product and engineering ownership and want to connect clinical services while preserving your experience.

The strength is the explicit product-practice boundary. The tradeoff is the need to maintain it through software changes, operational incidents and program expansion. Ask who detects a failed event and how staff can reconcile a patient’s status without reading raw logs. The API should support the care journey your clinical program needs, but the surrounding product still requires design and operations. Evaluate cost with the actual visit mix and retained workload rather than selecting solely on the lowest advertised encounter rate.

When is Cuvo a fuller operating alternative?

Cuvo offers managed brand packages with published setup and recurring pricing. Consider it when your reason for changing is the amount of nonclinical work your current arrangement leaves to your team.

The strength is a package you can map to an implementation checklist. The tradeoff is that you need to distinguish the included foundation from higher-tier automation, integrations and custom work. Ask whether an existing site can remain, what onboarding delivers and how operations are supported after launch. Compare the total commercial schedule with your current combination of vendors and internal labor. A fuller package can simplify coordination, but only if its boundaries match the tasks you actually want to outsource.

When should Tessic’s platform tiers be compared?

Tessic describes a managed platform with tiered setup, subscription and consultation costs. It belongs on the shortlist if you want a more defined brand operating package rather than only a replacement clinical interface.

The strength is a visible structure for comparing requirements. The tradeoff is plan dependence: identify which tier supplies the integrations, automations and brand count you need before modeling cost. Ask how a new program or brand changes implementation work and support responsibilities. Data portability should also be reviewed separately from an inbound migration service. Use the Tessic comparison to examine those distinctions instead of treating a broad feature list as proof that every workflow is included.

When is CareValidate relevant to a clinical-integration buyer?

CareValidate describes managed clinical and support infrastructure. Evaluate it if your next partner must address service coordination as well as the connection between intake and a clinician.

The strength to test is the operating model around patient needs and fulfillment. The tradeoff is the need for a detailed quote and responsibility map because numerical public pricing was not established in the reviewed pages. Ask how a clinical question, a commercial refund and a shipment problem are separated and assigned. For programs that depend on laboratory work, request a full exception demonstration. The right scope may be broader than your current clinical integration, so compare complete deliverables rather than an encounter price alone.

When should FUSE enter the shortlist?

FUSE offers different levels of build and launch involvement. It can suit a buyer who wants more control over configuring a branded experience or prefers a guided or managed implementation route.

The strength is choice in how the initial product is created. The tradeoff is the need to understand ongoing fees and service boundaries. Its percentage-based merchant service charge should be modeled separately from possible clinical, pharmacy and processing expenses. Resolve its public DIY monthly-price inconsistency in a written proposal. Ask how the proposed clinical programs are reviewed and how operational questions are handled after launch. A convenient builder and a suitable clinical-service arrangement are complementary requirements, not interchangeable evidence.

When is Healthie an appropriate software route?

Healthie’s Enterprise white-label option is relevant if your organization wants practice software while retaining or independently arranging clinical staffing. It is a different purchase from a partner supplying a complete clinical and commercial operating bundle.

The strength is a software foundation around an existing care organization. The tradeoff is that the staffing, fulfillment and administrative arrangements outside the contract still require owners. Ask what the white-label scope covers and how it works with your chosen providers and systems. Do not use an entry software price as a proxy for a nationwide staffed service. This route can be sensible for a practice with established operations, but it should not be presented as a drop-in clinical-network replacement.

How do you avoid a clinical-scope mismatch?

Start with a specific program description rather than a marketing category. MD Integrations’ official FAQ explicitly excludes controlled-substance prescribing. That fact should be considered directly, while availability at any alternative must be confirmed for the intended service. A broad hormone, longevity or wellness label does not establish an individual prescribing pathway.

Ask the clinical partner to explain visit requirements, follow-up, escalation and fulfillment for the program you want to offer. Keep commercial promises separate from clinical judgment. Selected TEHR peptide programs remain pending and are not open for prescribing or fulfillment. For existing patients, use the migration checklist to distinguish historical data transfer from ongoing care, orders and recurring payments. Choose a partner only after the operating and clinical descriptions agree about what will actually happen.

Who owns the transition of ongoing care?

Ask the incoming clinical organization how it reviews an established patient, what historical information it needs and how it handles a patient whose next step cannot proceed immediately. The brand should not promise automatic continuation of a treatment before the responsible clinician has made the appropriate decision. Coordinate patient communication, appointments and commercial subscriptions around that process. This is a separate workstream from importing records or changing the intake URL, and it needs a named owner on both sides.

What is the next useful step?

Compare two or three written scopes against the operating brief you developed. Use TEHR vs MD Integrations for the direct comparison, TEHR pricing for the commercial structure and a TEHR demo to test your own workflow. The resource library includes further implementation and procurement guides.

What else should you know?